BARINTHUS BIOTHERAPEUTICS PLC - AMERICAN DEPOSITAR

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

09 Aug 2022 15:15:00 By Nasdaq GlobeNewswire

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

07 Jul 2022 15:15:00 By Nasdaq GlobeNewswire

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

22 Jun 2022 05:00:00 By Nasdaq GlobeNewswire

Vaccitech to Present at the Jefferies Healthcare Conference

06 Jun 2022 15:15:00 By Nasdaq GlobeNewswire

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

06 Jun 2022 06:32:00 By Nasdaq GlobeNewswire

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

20 May 2022 10:30:00 By Nasdaq GlobeNewswire

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

11 May 2022 15:15:00 By Nasdaq GlobeNewswire

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

06 Apr 2022 15:15:00 By Nasdaq GlobeNewswire

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

25 Mar 2022 06:15:00 By Nasdaq GlobeNewswire

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

07 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

18 Jan 2022 02:00:00 By Nasdaq GlobeNewswire

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

13 Jan 2022 15:34:12 By Nasdaq GlobeNewswire

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

13 Dec 2021 15:05:00 By Nasdaq GlobeNewswire

Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV

07 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

24 Nov 2021 08:20:00 By Nasdaq GlobeNewswire

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Vaccitech to Present at the Jefferies London Healthcare Conference

10 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

04 Nov 2021 03:00:00 By Nasdaq GlobeNewswire

Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021

18 Oct 2021 07:00:01 By Nasdaq GlobeNewswire